en · de · es · fr · pt
epitalon-notes.peptides5388.com › Blog › Epitalon Structure And Research Origin — Worked Examples

Epitalon Structure And Research Origin — Worked Examples

By Editorial Desk · published 2026-01-31 · last reviewed 2026-02-23 · Blog

AEDG raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-02-23. Anything still debated is marked as such rather than presented as settled.

Epitalon Structure and Research Origin

(TG:@pojiaai)Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.

Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.

Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.

Identity and Research Background

Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.

The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.

Epitalon at a glance

PropertyValueNotes
Chemical classLinear tetrapeptideFour residues joined by three peptide bonds
SequenceAla-Glu-Asp-GlyCommonly abbreviated AEDG
Molecular formulaC14H22N4O9Free acid form
Monoisotopic massApproximately 390 DaMatches values reported from mass spectrometry
Net charge near neutral pHNegativeContributed by glutamate and aspartate side chains

Background and Proposed Mechanism

Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.

The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.

Related pages on this site

Epitalon Peptide Background and Structure

The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.

Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.

Chemical Identity and Research Background

Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.

The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.

Notes from published material

== Society == In March 2013, there was media coverage of a British 7-year-old boy named Owen, with chronically tense muscles due to SJS, and his three-legged pet dog. They became first-place winners of the 2013 Crufts Kennel Club's annual Friends for Life competition, which "celebrates dogs that have truly earned the title of man’s best friend through bravery, support or companionship". The dog was also awarded The Braveheart Honour in the ceremony of The British Animal Honours in April 2013 (Haatchi the dog). The two are featured in the book Haatchi & Little B (2014, ISBN 125-006-936-X) by Wendy Holden and on Haatchi's Facebook page. In 2016, 9-year-old Owen was featured in a TLC documentary series, Two in a Million, in which he met and formed a friendship with Giovanni, a 7-year-old American boy with SJS.

The fund bought the remaining 80% of Truist, together with Stone Point Capital, Clayton, Dubilier & Rice and other investors, for $15.5 billion in 2024. In May 2023, Mubadala agreed to buy a majority stake in a New York–based Fortress Investment Group from the SoftBank Group. The $3 billion takeover was intended to be closed in the first quarter of 2024. However, the deal that would give Mubadala 70% stakes in Fortress was being scrutinized by the U.S. national security officers. The deal, which raised concerns for the US over the UAE's ties with China, was being closely reviewed by the Committee on Foreign Investment in the US (Cfius). In May 2024, the regulatory body approved of the sale. A year later in April 2025, Mubadala and Fortress Investment started a $1 billion investment partnership. Mubadala increased its partnership with Aldar Properties in September 2024 with four joint ventures amounting to more than $8.2 billion across Abu Dhabi. In September 2024, Turkish Competition Authority confirmed that Mubadala applied to acquire Getir in entirety. In June 2024, Getir founders, Nazim Salur and Serkan Borancili, opposed Mubadala's restructuring plan that would separate profitable local grocery delivery operations with noncore businesses. Under the proposed plan, Mubadala was to acquire grocery delivery operations in exchange for $250 million investment. However, in January 2025, Salur alleged Mubadala of an “illegal coup” and vowed to take legal action against the Emirati firm.

Quantum dots are usually coated with organic capping ligands (typically with long hydrocarbon chains, such as oleic acid) to control growth, prevent aggregation, and to promote dispersion in solution. However, these organic coatings can lead to non-radiative recombination after photogeneration, meaning the generated charge carriers can be dissipated without photon emission (e.g. via phonons or trapping in defect states), which reduces fluorescent quantum yield, or the conversion efficiency of absorbed photons into emitted fluorescence. To combat this, a semiconductor layer can be grown surrounding the quantum dot core. Depending on the bandgaps of the core and shell materials, the fluorescent properties of the nanocrystals can be tuned. Furthermore, adjusting the thicknesses of each of the layers and overall size of the quantum dots can affect the photoluminescent emission wavelength — the quantum confinement effect tends to blueshift the emission spectra as the quantum dot decreases in size. There are 4 major categories of quantum dot heterostructures: type I, inverse type I, type II, and inverse type II. Type I quantum dots are composed of a semiconductor core encapsulated in a second semiconductor material with a larger bandgap, which can passivate non-radiative recombination sites at the surface of the quantum dots and improve quantum yield. Inverse type I quantum dots have a semiconductor layer with a smaller bandgap which leads to delocalized charge carriers in the shell.

Sources: en.wikipedia.org

Background from the literature

This exclusion is to ensure that a blended Scotch whisky produced from single malt(s) and single grain(s) distilled at the same distillery does not also qualify as single malt Scotch whisky or single grain Scotch whisky. Nearly 90% of the bottles of Scotch sold per year are blended whiskies. Three types of blends are defined for Scotch whisky:

In conclusion, of the 15 patients who had completed treatment, 7 developed varying degrees of hepatic failure and lactic acidosis and 5 died. Investigations found that affected patients suffered depletion of mitochondrial DNA (mtDNA) in both liver and muscle tissue, establishing mitochondrial dysfunction as a contributing mechanism to the observed toxicity. The FDA conducted a study into whether adverse effects could have been predicted beforehand. However, Dr. A Weinstein concluded that there was no way in which these adverse effects could have been predicted in laboratory animal studies or studies on patients.

However, the experimental chemistry of meitnerium has not received as much attention as that of the heavier elements from copernicium to livermorium. Lawrence Berkeley National Laboratory tried to synthesize 271Mt in 2002–2003 for a possible chemical investigation of meitnerium, as it was expected that it might be more stable than nearby isotopes due to having 162 neutrons, a magic number for deformed nuclei; its half-life was predicted to be a few seconds, long enough for a chemical investigation. However, no atoms of 271Mt were detected; this isotope of meitnerium is currently unknown. An experiment determining the chemical properties of a transactinide would need to compare a compound of that transactinide with analogous compounds of some of its lighter homologs: for example, in the chemical characterization of hassium, hassium tetroxide HsO4 was compared with the osmium analog, osmium tetroxide OsO4. In a preliminary step toward determining the chemical properties of meitnerium, the GSI attempted sublimation of rhodium(III) oxide Rh2O3 and rhodium(III) chloride RhCl3. However, macroscopic amounts of the oxide would not sublimate until 1000°C and the chloride would not until 780°C, and then only in the presence of carbon aerosol particles: these temperatures are far too high for such procedures to be used on meitnerium, as most of the current methods used for the investigation of the chemistry of superheavies do not work above 500°C.

Sources: en.wikipedia.org

Further detail

=== Assisted reproduction === PRP can be inoculated into the uterine cavity, to improve endometrial receptivity in cases of refractory endometrium. Studies have reported that intrauterine inoculation of PRP before embryo transfer can thicken the endometrium and improve reproductive prognosis. PRP has been studied for the management of Asherman's Syndrome. PRP can be inoculated experimentally into the ovary to promote ovarian tissue regeneration. The main applications would be in cases of diminished ovarian reserve or premature ovarian failure. A 2023 retrospective observational study reported PRP's effectiveness in rejuvenating ovarian fertility and viability in terms of "the influence of intraovarian injection of autologous PRP on the levels of E2". and pregnancy outcome in women treated with PRP who had a history of infertility, hormonal abnormalities, an absence of menstrual cycle, and premature ovarian failure in a single centre." A 2024 review showed that PRP is beneficial when used as intraovarian injections for women with decreased fertility. PRP used for fertility trouble increases AFC, number of cleavage embryos, and improves cancellation rate in women with poor ovarian reserve. However, "Although there was an improvement of baseline hormones (anti-Müllerian hormone, follicle-stimulating hormone, and estradiol) after intraovarian injection of PRP, this improvement failed to reach statistical significance (except the improvement of serum AMH analyzed in quasi-experimental studies)."

== Sources == This article incorporates text from a publication now in the public domain: Wiriath, Paul (1911). "France: History". In Chisholm, Hugh (ed.). Encyclopædia Britannica. Vol. 10 (11th ed.). Cambridge University Press. pp. 867–869.

=== September === 1 September A crisis emerges in schools, hospitals, and other public buildings, centred around the use of reinforced autoclaved aerated concrete (RAAC), a widely used but outdated material believed to be unsafe and in danger of crumbling. The announcements come just days before the beginning of the new academic year. Figures published by the Nationwide Building Society indicate UK house prices in August 2023 were 5.3% lower than those in August 2022, the largest fall since 2009. Octopus Energy announces plans to buy Shell Energy, giving Octopus an additional 1.4 million customers. 3 September Chancellor Jeremy Hunt says the UK government will "spend what it takes" to put right the problem of defective concrete in schools, and says that structural problems could be identified in more schools and other public buildings. Tesco chief executive Ken Murphy announces that staff at the retailer will be offered body cameras following a rise in violent incidents. UK government data indicates 872 migrants crossed the English Channel the previous day, the highest daily number of 2023. 4 September Labour leader Keir Starmer performs a cabinet reshuffle, as MPs return to Westminster after the summer break. This includes Angela Rayner becoming both Shadow Levelling Up Secretary and Shadow Deputy Prime Minister. Simon Byrne resigns as Chief Constable of the Police Service of Northern Ireland with immediate effect following a number of recent controversies.

Sources: en.wikipedia.org

Frequently asked questions

What is epitalon chemically?

It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.

Where did epitalon research originate?

The compound came out of work on epithalamin, a peptide preparation derived from pineal tissue, conducted largely in Russian laboratories. Later studies in other countries examined it mainly in cell cultures and animal models.

Is epitalon a naturally occurring peptide?

The tetrapeptide sequence is a synthetic construct rather than a described circulating peptide. It was derived by analogy to peptide fractions obtained from tissue extracts, not isolated from blood or tissue as such.

What is epitalon?

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.

Network